Cargando...
Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer
The introduction of enzalutamide and abiraterone has led to improvement in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, acquired resistance to enzalutamide and abiraterone therapies frequently develops within a short period in many patients. In the present study...
Guardado en:
| Publicado en: | Cancer Res |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4383695/ https://ncbi.nlm.nih.gov/pubmed/25649766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-3080 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|